Below are some of the key findings from the gene therapy for CNS disorders market analysis report:
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Global gene therapy for CNS disorders industry overview
Vendors are obtaining quicker approval for their novel gene therapies for CNS disorders with the help of special drug designations that are offered by various regulatory bodies. Special drug designations comprise of incentives such as fast track approval and tax credits and benefits released for new clinical research, providing economic relief to vendors. The continuous approval of gene therapy programs for CNS disorders will boost the adoption of gene therapy in various healthcare units.
Gene therapy for the treatment of CNS indications exhibits superior efficacy. This is attracting vendors to develop regenerative therapies and conduct studies for these indications. The substantial unmet need in the market for treating disorders such as Parkinson's disease is further encouraging vendors to conduct studies. This has led to a pipeline with multiple gene therapies for Parkinson's disease, various CNS indications, and multiple special drug designations. The presence of strong pipeline will support the quick approval of gene therapies for CNS disorders. Such factors will drive gene therapy for CNS disorders market growth at a CAGR of almost 27% during the forecast period.
Top gene therapy for CNS disorders companies covered in this market research report
The gene therapy for CNS disorders market is highly concentrated. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by companies, this gene therapy for CNS disorders industry analysis report will help clients identify new growth opportunities and design effective strategies to improve their market share.
The report offers a complete analysis of various companies including:
- Biogen
- bluebird bio, Inc.
- Novartis AG
- Pfizer Inc.
- Voyager Therapeutics
Gene therapy for CNS disorders market segmentation based on geographic regions
- Asia
- Europe
- North America
- ROW
North America will account for the largest gene therapy for CNS disorders market share throughout the forecast period. The increasing number of novel gene therapies being developed for various CNS disorders is one of the major reasons for the high growth of the gene therapy for CNS disorders market in this region.
Gene therapy for CNS disorders market segmentation based on indication
- SMA
- Others
The SMA segment will account for the highest gene therapy for CNS disorders market share in 2018. Because of factors such as the high prevalence of SMA across all genders and races and the availability of therapy with superior efficacy, the segment will continue to dominate the market throughout the forecast period.
Key highlights of the global gene therapy for CNS disorders market for the forecast years 2019-2023:
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the gene therapy for CNS disorders market during the next five years
- Precise estimation of the global gene therapy for CNS disorders market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the gene therapy for CNS disorders industry across various geographies such as Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of gene therapy for CNS disorders companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch